These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 31938368

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAFV600E mutation.
    Wang K, Li Y, Song N, Che X, Hou K, Xu L, Bai M, Wang Q, Wang Y, Zhou Y, Cao M, Liu Y, Zhang J.
    J Cell Biochem; 2019 Apr; 120(4):5315-5325. PubMed ID: 30320916
    [Abstract] [Full Text] [Related]

  • 4. miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
    Grzywa TM, Klicka K, Paskal W, Dudkiewicz J, Wejman J, Pyzlak M, Włodarski PK.
    PLoS One; 2020 Apr; 15(6):e0234707. PubMed ID: 32555626
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma.
    Hüser L, Kokkaleniou MM, Granados K, Dworacek J, Federico A, Vierthaler M, Novak D, Arkhypov I, Hielscher T, Umansky V, Altevogt P, Utikal J.
    Cancers (Basel); 2020 Dec 14; 12(12):. PubMed ID: 33327495
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.
    Jiang CC, Croft A, Tseng HY, Guo ST, Jin L, Hersey P, Zhang XD.
    Oncogene; 2014 May 15; 33(20):2577-88. PubMed ID: 23770856
    [Abstract] [Full Text] [Related]

  • 15. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
    Zhao B, Cheng X, Zhou X.
    Melanoma Res; 2018 Dec 15; 28(6):521-526. PubMed ID: 30192303
    [Abstract] [Full Text] [Related]

  • 16. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M, Wu L, Zhang K, Wang H, Wu S, O'Connell D, Gao T, Zhong H, Yang Y.
    Cell Signal; 2018 Jan 15; 42():30-43. PubMed ID: 28982601
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.
    Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML, White E, Rodriguez-Rodriguez L, Mehnert JM, Ganesan S.
    Clin Cancer Res; 2017 Sep 15; 23(18):5631-5638. PubMed ID: 28539463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.